NCT06098898View on ClinicalTrials.gov

Safety and Efficacy of NK510 to Treat Gastric Cancer

EARLY_PHASE1Enrolling by invitationINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

November 1, 2024

Conditions
Gastric Cancer
Interventions
DRUG

NK510

NK510 will be administered through intravenous infusion.3 infusions on Day 0，Day 2 and day 3 for a cycle，for a total of two cycles.

DRUG

Tislelizumab，atezolizumab or Trastuzumab

Administer according to the instructions.

Trial Locations (1)

Unknown

Shanghai Tenth People's Hospital, Shanghai

All Listed Sponsors
collaborator

Shanghai 10th People's Hospital

OTHER

lead

Base Therapeutics (Shanghai) Co., Ltd.

INDUSTRY